Vita Life Sciences Limited Provides Earnings Guidance for Half Year Ending June 30, 2024. For the period, the company expects Sales of $39.0 million - $40.0 million. The Company remains confident in maintaining revenue growth across its core markets in Australia, Malaysia and Singapore.

First-half performance has been buoyed by robust sales, reflecting the strength of the Group's diverse product portfolio and effective channel strategies. Group operations continue to track against expectations. Looking ahead, there will be a continued focus on investment in trade and brand advertising, aligned with evolving channel dynamics.

Management remains positive in delivering ongoing shareholder value and returns. Pre-tax Profit: $5.5 million -$6.0 million.